Morningstar
•
Jul 15, 2026
Ionis Pharmaceuticals, Inc.: Biogen and Ionis: Mixed Phase 2 Data for Alzheimer's Disease Candidate
Summary
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
Sep 02, 2026
•
ALNY
ARWR: Lowering target price to $87.00
Sep 02, 2026
•
ARWR
EXEL: Raising target price to $63.00
Sep 02, 2026
•
EXEL
SRPT: Raising target price to $17.00
Sep 02, 2026
•
SRPT
ACAD: Lowering target price to $30.00
Sep 02, 2026
•
ACAD
